Publications by authors named "Matthew Monberg"

Claim this Profile
I
Impact of the COVID-19 pandemic on cancer recurrence rates in patients with ovarian cancer.
Amrita Mukherjee, Natalie Ayoub, Lanfang Xu, Kimberly L Cannavale, Alec D Gilfillan, Matthew J Monberg

Gynecol Oncol Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence in gynecologic cancers presented at key oncology conferences in the United States: Distribution and factors related to high-tier acceptance.
Elizabeth A Szamreta, Mansi Modi, Ramu Periyasamy, Bhavani Yamsani, Pattabhi Machiraju, Matthew Monberg

PLoS One· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States.
Bradley J Monk, Sophie van Mens, Oliver Hale, Jennifer Boer, Frank van Hees, Matthew Monberg

Oncol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Remission Rates in Patients With Epithelial Ovarian Cancer Before and After the Onset of the COVID 19 Pandemic in an Integrated Healthcare Delivery System.
Amrita Mukherjee, Natalie Ayoub, Lanfang Xu, Kimberly L Cannavale, Alec D Gilfillan, Matthew J Monberg

Cancer Manag Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers.
Matthew J Monberg, Steve Keefe, Vassiliki Karantza, Konstantinos Tryfonidis, Sarper Toker

Oncol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using AI and Social Media to Understand Health Disparities for Transgender Cancer Care.
Augustine Annan, Yeran Li, Jingcheng Du, Yezhou Sun, A I Asante-Facey, Matthew Monberg

JAMA Netw Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer.
Alexandra Diggs, Yongmei Huang, Alexander Melamed, Elizabeh Szamreta, Matthew Joseph Monberg

Int J Gynecol Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer.
Francesca Coutinho, Mugdha Gokhale, Charlotte Doran, Matthew Monberg, Karin Yamada

Cancer Treat Res Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer.
Amrita Mukherjee, Natalie Shammas, Lanfang Xu, Kimberly L Cannavale, Alec D Gilfillan, Matthew Monberg

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
Dana M Chase, Srinivas Annavarapu, Wan-Yu Tseng, Junxin Shi, Elizabeth Szamreta, Matthew Monberg

Gynecol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Elizabeth A Szamreta, Matthew J Monberg, Kaushal D Desai, Yeran Li, Megan Othus

Gynecol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States.
Mugdha Gokhale, Rebekah Yu, Matthew Monberg, Cumhur Tekin, Lei Chen

Cancer Treat Res Commun· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
David Elsea, Dominic Muston, Lin Fan, Adela Mihai, Yang Meng, Matthew Monberg

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of ovarian cancer in the USA from 2007 to 2018: evidence from the Medical Expenditure Panel Survey.
Elizabeth A Szamreta, Wei-Jhih Wang, Ruchit Shah, Shelby Corman, Matthew Monberg

Future Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics.
Richard W DeClue, Elizabeth A Szamreta, Santosh Gautam, Maxine D Fisher, Matthew J Monberg

Future Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bradley J Monk, Krishnansu S Tewari, Coraline Dubot, M Valeria Caceres, Kosei Hasegawa, Matthew J Monberg

Lancet Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons, Matthew Monberg

Pharmacoecon Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons, Matthew Monberg

Pharmacoecon Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer.
Charlotte R Gamble, Ling Chen, Elizabeth Szamreta, Matthew Monberg, Dawn Hershman

Arch Gynecol Obstet· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.
Lin Fan, Yuanyuan Zhang, Peter Maguire, Dominic Muston, Matthew Monberg

J Mark Access Health Policy· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Rebecca L Stone, M Janelle Cambron-Mellott, Kathleen Beusterien, Martine C Maculaitis, Stephanie Ritz, Matthew Monberg

Future Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Wei Gao, Dominic Muston, Matthew Monberg, Kimmie McLaurin, Robert Hettle

Pharmacoeconomics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Dominic Muston, Robert Hettle, Matthew Monberg, Kimmie K McLaurin, Wei Gao

Gynecol Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
Changxia Shao, Jinan Liu, Wei Zhou, Monika K Raut, Matthew Monberg

Leuk Lymphoma· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.
Hak Choy, David E Gerber, Jeffrey D Bradley, Puneeth Iyengar, Matthew Monberg

Lung Cancer· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis